Neogenix Oncology: Pancreatic and Colocrectal Cancer Update

By Andrea: http://nursingoncologyjob.com

Neogenix Oncology, Inc. recently announced that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

Neogenix has developed an ELISA serum biomarker using, NPC-1C, its novel, proprietary chimeric antibody that selectively targets pancreatic and colorectal cancer. The prospective study, being conducted at Conemaugh Cancer Center, in Johnstown, PA, provides for the evaluation of blood serum samples from patients confirmed with pancreatic or colon cancer. Preliminary results demonstrate the Neogenix biomarker assay’s ability to differentiate between blood serum of healthy donors and that of patients with colorectal or pancreatic cancer. In addition, the results of the NPC-1C biomarker test indicate superior sensitivity as compared to commercially available CEA and CA19-9 assays. A complete data set will be presented at the ASCO Meeting.

"We are very excited about the study results which hold promise for the early detection of these devastating diseases. These tests could provide a real hope for patients by enabling early intervention and substantially improved clinical outcome,” says Philip M. Arlen, M.D, President and CEO of Neogenix Oncology.